Circio Holding Asa Is A Clinical Stage Biotechnology Company Based In Oslonorwaythe Company Specializes In Developing Innovative Rna Based Therapeutics And Immunotherapies Aimed At Treating Challenging Diseases Through Genetic Medicine Circio Operates Two Main Programsthe Development Of Circular Rnacircrnamedicines And Cancer Immunotherapythe Circrna Program Utilizes Vector Based Technology In Collaboration With Profmichael Uhlinae S Team At Karolinska Institutetin Cancer Immunotherapycircio Is Advancing Tg01A Cancer Vaccine Targeting Kras Driver Mutationsand Oncos 102A Genetically Modified Oncolytic Adenovirus Currently In Clinical Trials In The U Sand Norwaythe Company Emphasizes Partnerships With Academic Institutions And Is Focused On Securing Financing To Support Its Clinical Programs
